Browsing articles in "Unipolar Depression"


Studies Show Psilocybin Therapy Has Potential For Anorexia Nervosa And Severe Treatment-Resistant Depression
May 18, 2022   

Recent positive data was announced from two investigator-initiated studies demonstrating the potential of COMP360, a psilocybin therapy for anorexia nervosa and severe treatment-resistant depression. These two studies provided support for continued research at a larger scale to elucidate the therapeutic potential of psilocybin...
 Continue reading
Factors Associated With Professional Mental Health Service Use Among Adults With Suicidal Ideation
May 16, 2022   

Fewer than half of people who die by suicide engage with mental health services in the year prior to death. However, few studies have examined which factors are associated with professional mental health services among people experiencing suicidal ideation. A cross-sectional survey study of...
 Continue reading (Members only)
Highlights From the 2022 NEI Synapse: Depression Throughout the Female Lifespan
April 23, 2022   

At the 2022 NEI Synapse, Dr. Mary Kimmel discussed best practices for diagnosing and treating depression in women throughout their lives in a CME/CE session titled, “Ups and Downs: Diagnosing and Treating Depression Throughout the Female Lifespan.”
 Continue reading
Vortioxetine in Patients with Major Depressive and Alcohol Use Disorders
April 17, 2022   

Major depressive disorder (MDD) is often found comorbid with alcohol use disorder (AUD) and patients with MDD+AUD often have a worsened illness and prognosis. Response of MDD+AUD to classic antidepressants, including selective serotonin reuptake inhibitors (SSRIs), norepinephrine serotonin reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs) is often unsatisfactory. In this study...
 Continue reading (Members only)
FDA Approves First Orally Dissolving Sublingual Film For Schizophrenia-Associated Agitation
April 6, 2022   

The U.S. Food and Drug Administration has approved an orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia or bipolar I or II disorder. ...
 Continue reading
Prolonged Grief Disorder Diagnostic Criteria in DSM-5-TR
March 23, 2022   

New diagnostic criteria for prolonged grief disorder (PGD) have been presented in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). PGD not only places patients at risk for intense distress, but also poor physical health, shortened life expectancy, and suicide...
 Continue reading
Research Identifies Differences Between Acute LSD and Psilocybin
March 19, 2022   

As interest grows for using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy, studies comparing the two are necessary. A study with a double-blind, placebo-controlled, crossover design and five experimental test sessions investigated acute responses to...
 Continue reading (Members only)
Neural Circuits Of Anxiolytic And Antidepressant Pherine Molecules
March 16, 2022   

Pherines are a novel class of synthetic neuroactive steroids formulated to engage human nasal chemosensory receptors. They are administered intranasally and detected by olfactory afferents wired directly to the limbic amygdala. Due to this mechanism, they have rapid and potent effects on behavior and the autonomic nervous system...
 Continue reading
Combining Antidepressants Found Superior to Monotherapy for Treatment of Acute Depression
February 18, 2022   

A recent systematic review and meta-analysis of randomized clinical trials compared combinations of two antidepressants with antidepressant monotherapy in adults with acute depression found that....
 Continue reading
Efficacy and Tolerability of Augmenting Agents for Major Depression
February 15, 2022   

Using adjunctive pharmacological agents for treatment-resistant depression is a common treatment strategy. However, the relative efficacy and tolerability of common adjunctive treatments has not been adequately studied, which can make it difficult to select the appropriate agent...
 Continue reading (Members only)
Top of Page